Gluetacs Therapeutics Announces IND Approval of Its Second Molecular Glue Degrader Pipeline GT929 from FDA

ON：2023-10-27 TAG：GLUETACS THERAPEUTICS

PRESS RELEASE

Shanghai, China – 27 Oct 2023

Gluetacs Therapeutics Announces IND Approval of Its Second Molecular Glue Degrader Pipeline GT929 from FDA

Today, the second molecular glue degrader pipeline of Gluetacs Therapeutics, Class 1 new drug GT929 capsule, was approved by the U.S. Food and Drug Administration (FDA) to initiate clinical trial for the treatment of patients with Hematological Malignancies.

GT929 was previously approved by the National Medical Products Administration (NMPA) for clinical trial on July 24, 2023, and is expected to enroll the first patient in China’s Phase I clinical study by the end of 2023.

This is the second pipeline approved for clinical trials in both China and the U.S. besides GT919, marking another milestone in the globalization process of Gluetacs Therapeutics.